(2R)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-3-hydroxy-2-(2-phenylethylsulfonylamino)propanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-3-hydroxy-2-(2-phenylethylsulfonylamino)propanamide
• 化学式: C₂₀H₃₂N₆O₆S
• 分子量: 484.6
• InChiKey: MTWIXLSCVOLDOW-BHYGNILZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  33
• 可旋转键数：
  15
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  214
• 氢给体数：
  6
• 氢受体数：
  8

文献信息

• INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION
  申请人：CORVAS INTERNATIONAL, INC.

  公开号：EP1100814A2

  公开（公告）日：2001-05-23
• US6432922B1
  申请人：——

  公开号：US6432922B1

  公开（公告）日：2002-08-13
• [EN] INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION<br/>[FR] INHIBITEURS D'UROKINASE ET DE LA FORMATION DE VAISSEAUX SANGUINS
  申请人：CORVAS INT INC

  公开号：WO2000005245A2

  公开（公告）日：2000-02-03

  Novel compounds having activity inhibitors of urokinase and in reducing or inhibiting blood vessel formation are provided. These compounds have an arginine or arginine mimic aldehyde or an arginine ketoamide group at P1. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.